AbbVie Inc

3 de nov. de 2026, 23:02 UTC

AbbVie Inc. is trading lower in after-market hours, having retraced from an earlier gain to a current loss, near the lower end of today's range.

2 de nov. de 2026, 23:06 UTC

AbbVie Inc. gains after director Jennifer L. Davis resigns to become CEO at Align Technology; UBS raises price target to $295 while maintaining Neutral rating.

30 de out. de 2026, 20:03 UTC

AbbVie reports Q3 sales of $17.404 billion, exceeding estimates, and raises full-year revenue guidance to $67.8 billion, while announcing a 5.2% dividend increase.

29 de out. de 2026, 23:02 UTC

AbbVie Inc. announced the publication of results from the Phase 3 TEMPLE study in The Lancet Neurology.

28 de out. de 2026, 23:02 UTC

AbbVie Inc. is trading modestly higher in after-market hours, supported by positive results from Eli Lilly's trial and Amgen's upcoming financial webcast.

27 de out. de 2026, 20:07 UTC

AbbVie submits a Biologics License Application for etentamig, showing a 74% response rate in Phase 3 CERVINO trial for relapsed multiple myeloma.

26 de out. de 2026, 19:16 UTC

AbbVie is set to announce Q3 FY2026 earnings on October 30, with an expected EPS of $3.78 and revenue of $17.4 billion.

23 de out. de 2026, 23:06 UTC

AbbVie receives FDA approval for a subcutaneous induction regimen of SKYRIZI® for adults with moderately to severely active Crohn's disease.

22 de out. de 2026, 23:01 UTC

AbbVie announces positive topline results from the Phase 3 INTREPID study evaluating lutikizumab for moderate to severe hidradenitis suppurativa.

21 de out. de 2026, 23:41 UTC

AbbVie Inc shares are trading modestly lower in after-market hours.

20 de out. de 2026, 20:08 UTC

AbbVie Inc. received Health Canada approval for SKYRIZI to treat children with moderate to severe plaque psoriasis, expanding pediatric treatment options.

19 de out. de 2026, 20:07 UTC

AbbVie announces positive Phase 2a study results for ABBV-466 in Crohn's disease, with remission rates of 30.2% at Week 12 and 40.5% at Week 24.

16 de out. de 2026, 23:51 UTC

AbbVie Inc is trading modestly higher in after-market hours, reaching its highest cumulative return of the day and positioned above its 20-day moving average.

15 de out. de 2026, 23:01 UTC

AbbVie expands its Board of Directors by appointing Dr. John M. Carethers, increasing the board size to 13 members and confirming his independent status.

14 de out. de 2026, 23:01 UTC

AbbVie Inc shares advanced modestly during after-market hours on Wednesday, continuing a pattern of higher daily closes since the previous session.

13 de out. de 2026, 23:56 UTC

AbbVie Inc saw a modest uptick in after-market trading, gaining ground since Tuesday's close, supported by a generally positive backdrop for the biotechnology sector.

12 de out. de 2026, 23:06 UTC

AbbVie Inc shares advanced in after-market trading, marking the ninth consecutive session of higher closes and settling above its 20-day moving average.

9 de out. de 2026, 23:00 UTC

AbbVie Inc. is experiencing a notable decline in after-hours trading, reaching its lowest point since Friday's close, reversing a trend of higher closes.

8 de out. de 2026, 23:05 UTC

AbbVie Inc shares are slightly lower in after-market trading, dipping just below Thursday's close after reaching an early peak.

7 de out. de 2026, 23:05 UTC

AbbVie Inc received FDA Breakthrough Therapy Designations for telisotuzumab adizutecan, with the stock modestly higher in after-market trading amid strong investor interest.

6 de out. de 2026, 23:15 UTC

AbbVie Inc's shares are trading modestly lower in after-market hours, continuing a recent trend of fluctuations within a narrow range.

5 de out. de 2026, 23:00 UTC

AbbVie Inc. updated its Q3 adjusted diluted EPS guidance to $3.73-$3.77, while revising 2026 full-year guidance down to $13.76-$13.96; shares were roughly flat in after-market trading.

2 de out. de 2026, 23:05 UTC

AbbVie Inc has seen a slight increase in after-market trading, continuing its advance since Friday's close and fluctuating near the upper end of its one-month trading range.

1 de out. de 2026, 23:15 UTC

AbbVie Inc is experiencing routine after-market trading, advancing slightly since Thursday's close, despite retracing to near the low end of today's range.

30 de set. de 2026, 23:00 UTC

AbbVie shares are trading modestly higher in after-market hours following the announcement of a late-breaker presentation at the 2026 European Academy of Dermatology Congress.

29 de set. de 2026, 23:45 UTC

AbbVie Inc is seeing a slight increase in after-market trading, remaining above its 20-day moving average and near the upper end of its one-month range.

28 de set. de 2026, 23:30 UTC

AbbVie Inc's stock is trading higher in after-market hours following FDA approval of JUVMO™ tablets, the first selective D1/D5 receptor agonist for Parkinson's disease.

25 de set. de 2026, 23:51 UTC

AbbVie Inc received FDA approval for Juvmo (Tavapadon), a Parkinson's treatment, contributing to a modest rise in shares during after-market trading.

24 de set. de 2026, 20:07 UTC

AbbVie Inc. shares fell slightly despite receiving Health Canada approval for EPKINLY in combination with lenalidomide and rituximab for treating follicular lymphoma.

23 de set. de 2026, 23:01 UTC

AbbVie Inc. is down slightly in after-market trading, pulling back from an earlier session high, with a "Sell" rating and a price target of $191.